Search

everythinglearnresearchcommunity

for

Search:↓

Use specific tools to measure quality of life in alopecia areata patients and improve future treatments.

The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.

The Italian version of a relationship scale was adapted for cancer patients, showing some differences from the original and suggesting its use could improve therapy and treatment adherence.

The Chinese version of the PCOS quality of life questionnaire is reliable and valid for Chinese-speaking women with PCOS.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

A woman with advanced eye cancer went into complete remission using a combination of immunotherapy and topical treatments.

Imiquimod 5% cream may not work for treating scrotal extramammary Paget disease.

Understanding patients' views on their illness can help improve their disease management.

Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair growth cells and aiding self-repair.

No current patient-reported outcome measure fully meets FDA requirements for alopecia treatments.

Patients follow treatment well, but many change medicines; good information helps compliance.

A specific genetic trait in tumor cells is linked to longer survival without disease in certain lymphoma patients.

Porocarcinoma generally has low rates of recurrence, spread to lymph nodes, and death.

Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.

Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.

Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.

Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.

The committee decided not to approve the drug due to low effectiveness and high risks.

PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.

The HAIR-Q is a reliable tool for assessing patient satisfaction with hair loss treatments.

European dermatological guidelines vary in quality, with some highly rated, but improvements are needed in applicability and consistency.

FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.

Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.

The treatment was effective and tolerable for advanced gastric cancer.

ALRV5XR significantly improves hair density in women with hair loss and is well-tolerated.

Men with better urinary symptoms have a lower risk of death.

Topical GT20029 effectively promotes hair regrowth and is well-tolerated.